FDA Cardiovascular & Renal Drugs Advisory Committee
Executive Summary
Centocor's ReoPro (abciximab) PLA (93-1057) will be reviewed for use in high-risk angioplasty during June 9 meeting. ReoPro (formerly CentoRx) is licensed to Lilly. Also on June 9, the committee will review Ciba-Geigy's NDA (20-364) for combination benazepril/amlodipine for treatment of hypertension. The product combines the active ingredients of Ciba's Lotensin and Pfizer's Norvasc and is being developed under a licensing agreement with Pfizer. On June 10, the committee will discuss an accelerated dosing schedule for Genentech's Activase ("The Pink Sheet" May 16, T&G-2). The meeting will take place at NIH's Masur Auditorium beginning at 9 a.m. both days